Lucid Diagnostics study shows 95% cell collection success with EsoCheck in 11,991 patients

Bitget2026/11/03 13:15

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lucid Diagnostics announced published real-world study results for its EsoGuard esophageal precancer test in the peer-reviewed journal Diagnostics.
The study covered 11,991 at-risk patients tested from January 2023 through June 2024.
EsoCheck cell collection was rapid and well tolerated across operators, including newly trained personnel; no device-related adverse events were reported.
The findings support broader clinical deployment as the company accelerates commercialization, with EsoGuard now fully reimbursed by Medicare nationwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611030815PR_NEWS_USPR_____NY87684) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lucid Diagnostics study shows 95% cell collection success with EsoCheck in 11,991 patients

You may also like

Crypto prices